0000000000251070

AUTHOR

John Kennedy

showing 2 related works from this author

Search for an excess of events with an identical flavour lepton pair and significant missing transverse momentum in root s=7 TeV proton-proton collis…

2011

Results are presented of a search for supersymmetric particles decaying into final states with significant missing transverse momentum and exactly two identical flavour leptons (e or mu) of opposite charge in sqrt{s}=7 TeV collisions at the Large Hadron Collider. This channel is particularly sensitive to supersymmetric particle cascade decays producing flavour correlated lepton pairs. Flavour uncorrelated backgrounds are subtracted using a sample of opposite flavour lepton pair events. Observation of an excess beyond Standard Model expectations following this subtraction procedure would offer one of the best routes to measuring the masses of supersymmetric particles. In a data sample corres…

Particle physicsPhysics and Astronomy (miscellaneous)Physics beyond the Standard ModelFlavourSupergauge TransformationsFOS: Physical sciencesddc:500.2Parameter space01 natural sciences530Settore FIS/04 - Fisica Nucleare e SubnucleareHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)Pionsparticle: cascade decay ; sparticle: search for ; electron: pair production ; muon: pair production ; p p: inelastic scattering ; transverse momentum: missing-energy ; supersymmetry: parameter space ; CERN LHC Coll ; new physics ; ATLAS ; dilepton: mass spectrum ; experimental results ; 7000 GeV-cmsPions0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]FysikHigh Energy Physics010306 general physicsEngineering (miscellaneous)PhysicsLarge Hadron ColliderScience & TechnologyATLAS detector010308 nuclear & particles physicsSettore FIS/01 - Fisica SperimentaleHigh Energy Physics::PhenomenologyATLASGeneratorsCascadeTransverse momentumPhysical SciencesExperimental High Energy PhysicsComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFísica nuclearHigh Energy Physics::ExperimentLHCParticle Physics - ExperimentLeptonModel
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct